Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors
{{output}}
Objective: To predict the incidence of immune-related Adverse Events (irAEs) in patients with recurrent or metastatic Nasopharyngeal Carcinoma (NPC) treated with Programmed Death-Ligand 1 (PD-L1) inhibitors, this study developed ... ...
